| Bid | 1.03 |
| Market Cap | 90.98M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | -0.82 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.06 |
| Volume | 531,119 |
| Avg. Volume (20D) | 1,037,436 |
| Open | 1.03 |
| Previous Close | 1.00 |
| Day's Range | 0.98 - 1.03 |
| 52-Week Range | 0.97 - 2.11 |
| Beta | undefined |
About IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company i...
Analyst Forecast
According to 7 analyst ratings, the average rating for IMUX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 890.10% from the latest price.
4 days ago · proactiveinvestors.com
Immunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMIImmunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company's progress in advancing its novel therapy vidofludimus calcium. He discussed the significant mile...
1 week ago · proactiveinvestors.com
Immunic eyes key data readout from multiple sclerosis trial in 2025Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data readouts and securing significant funding to pr...
1 month ago · proactiveinvestors.com
Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMIImmunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company's Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet G...
2 months ago · proactiveinvestors.com
Immunic reports positive Phase 1 results for celiac disease therapy published in The LancetImmunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The Lancet Gastroenterology & Hepatology. The stud...
2 months ago · proactiveinvestors.com
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestonesImmunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple scleros...
2 months ago · proactiveinvestors.com
Immunic Phase 3 MS study advances following positive recommendation from independent committeeImmunic Inc (NASDAQ:IMUX) announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program which is investigating its lead asset vidofludimus calcium in relapsing multiple...